2016-01-07

Camurus's initial public offering a success

On Thursday December 3, 2015, Camurus started its first day of trading on Nasdaq Stockholm. The share price increased considerably during the first day and Camurus is now the largest company in the biotechnology sector on Nasdaq Stockholm

The price of the Camurus share was set at SEK 57, but at closing time the share was noted at SEK 65,5, an increase of no less than 15,7 percent. The upturn meant that the market capitalization of Camurus was close to SEK 2,5 million at the end of the day. Today (January 2016) the market capitalization is about SEK 2,8 million.

Sandberg Development will remain the largest shareholder in Camurus and will hold appr. 54 percent of the total number of shares in the company.

Latest news

2019-08-26

Camurus’ treatment Buvidal® subsidised in Australia

Australia has announced that Camurus’ treatment Buvidal® (buprenorphine) will be listed through the Pharmaceutical B…

Read more

2019-08-07

Three new products from ISEC

ISEC has launched three new products for better and safer surveillance of radioactive environments.

Read more

2019-07-23

Positive outcome for Camurus in court proceedings regarding final approval of Brixadi™ in the US

Camurus’ partner Braeburn have received a positive outcome in the US court proceedings which were initiated in April…

Read more

2019-06-20

FDA grants Camurus IND application to enter Phase 3 study with CAM2029 for treatment of acromegaly

The FDA has approved Camurus’ Investigational New Drug application to initiate a Phase 3 study with CAM2029 once-mon…

Read more

2019-06-17

Introducing the chemical-free office

Starting June 2019, all Sandberg Development's office and production facilities will be cleaned and washed with DIRO…

Read more